Published in Cancer Res on May 01, 2007
Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69
Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res (2010) 3.35
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med (2013) 2.18
The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol (2011) 2.16
Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis (2008) 2.11
The vascular basement membrane as "soil" in brain metastasis. PLoS One (2009) 1.95
In vivo animal models for studying brain metastasis: value and limitations. Clin Exp Metastasis (2013) 1.52
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res (2010) 1.48
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res (2011) 1.46
ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta (2009) 1.41
Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS One (2009) 1.37
Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res (2009) 1.36
Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC Cancer (2009) 1.26
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res (2010) 1.16
Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis (2008) 1.14
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol (2009) 1.12
Multimodal in vivo imaging and blood monitoring of intrinsic and extrinsic apoptosis. Mol Ther (2011) 1.11
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res (2009) 1.10
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther (2009) 1.09
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A (2012) 1.09
The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer (2012) 1.08
SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res (2013) 1.06
Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One (2009) 1.05
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol (2011) 1.03
Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Med (2012) 1.03
Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. J Neurooncol (2012) 1.03
Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation. J Transl Med (2009) 1.03
Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis. Oncogene (2012) 1.00
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol (2008) 0.99
Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer (2010) 0.98
Roadblocks to translational advances on metastasis research. Nat Med (2013) 0.98
Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia (2015) 0.98
Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci (2013) 0.96
Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnol (2012) 0.96
Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage. Cancer Res (2012) 0.96
Metastasis of Breast Tumor Cells to Brain Is Suppressed by Phenethyl Isothiocyanate in a Novel In Vivo Metastasis Model. PLoS One (2013) 0.95
Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol (2010) 0.95
Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res (2011) 0.95
Breast cancer metastasis: issues for the personalization of its prevention and treatment. Am J Pathol (2013) 0.95
Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget (2014) 0.94
Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation. Cancer Res (2009) 0.94
Innovative therapeutic strategies in the treatment of brain metastases. Int J Mol Sci (2013) 0.94
Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res (2016) 0.92
Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI. Clin Exp Metastasis (2011) 0.92
Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells. Am J Pathol (2013) 0.91
S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. Am J Transl Res (2014) 0.90
In vivo single scan detection of both iron-labeled cells and breast cancer metastases in the mouse brain using balanced steady-state free precession imaging at 1.5 T. J Magn Reson Imaging (2011) 0.90
In Vivo Magnetic Resonance Imaging for Investigating the Development and Distribution of Experimental Brain Metastases due to Breast Cancer. Transl Oncol (2012) 0.88
Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity. Breast Cancer Res (2014) 0.88
Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol (2015) 0.87
DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer. J Natl Cancer Inst (2014) 0.87
HER2 mediated de novo production of TGFβ leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancer. Mol Oncol (2014) 0.87
Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Clin Cancer Res (2014) 0.87
PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype. Mol Cancer (2011) 0.86
Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumors. Am J Pathol (2011) 0.85
Molecular interactions in the development of brain metastases. Int J Mol Sci (2013) 0.85
Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. Oncotarget (2015) 0.85
Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis. Mol Cell Proteomics (2015) 0.84
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS One (2011) 0.84
Role of the neural niche in brain metastatic cancer. Cancer Res (2014) 0.84
Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer. Clin Exp Metastasis (2016) 0.83
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist (2012) 0.83
Longitudinal MRI evaluation of intracranial development and vascular characteristics of breast cancer brain metastases in a mouse model. PLoS One (2013) 0.83
Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano (2016) 0.83
Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells. Oncotarget (2015) 0.83
Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene (2015) 0.82
Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. Breast Cancer Res Treat (2014) 0.82
PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. J Neurooncol (2014) 0.82
Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. Stem Cells (2015) 0.81
HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series. Int J Mol Sci (2013) 0.81
Interactions between αv-Integrin and HER2 and Their Role in the Invasive Phenotype of Breast Cancer Cells In Vitro and in Rat Brain. PLoS One (2015) 0.81
Targeted Therapies for Brain Metastases from Breast Cancer. Int J Mol Sci (2016) 0.80
Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain. Clin Cancer Res (2013) 0.80
The molecular genomics of metastatic brain tumours. OA Mol Oncol (2013) 0.80
Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer. Sci Rep (2015) 0.80
Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer. Clin Cancer Res (2016) 0.80
EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci (Elite Ed) (2016) 0.79
Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells. Biochem Biophys Res Commun (2015) 0.79
Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment. Radiat Oncol J (2016) 0.79
The possibility of lapatinib treatment for breast cancer patients with central nervous system metastases. Case study and literature review. Contemp Oncol (Pozn) (2013) 0.79
Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. Jpn J Clin Oncol (2010) 0.79
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2012) 0.79
Molecular aspects of breast cancer metastasis to the brain. Genet Res Int (2011) 0.79
Improved anti-proliferative effect of doxorubicin-containing polymer nanoparticles upon surface modification with cationic groups. J Mater Chem (2012) 0.79
Identification of breast cancer cell subtypes sensitive to ATG4B inhibition. Oncotarget (2016) 0.78
Analysis of radiation therapy in a model of triple-negative breast cancer brain metastasis. Clin Exp Metastasis (2015) 0.78
Clinical significance of KISS1 protein expression for brain invasion and metastasis. Cancer (2011) 0.78
Understanding Heterogeneity and Permeability of Brain Metastases in Murine Models of HER2-Positive Breast Cancer Through Magnetic Resonance Imaging: Implications for Detection and Therapy. Transl Oncol (2015) 0.78
Fluoxetine modulates breast cancer metastasis to the brain in a murine model. BMC Cancer (2014) 0.77
A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier. Cancer Prev Res (Phila) (2014) 0.77
Ultrasound imaging-guided intracardiac injection to develop a mouse model of breast cancer brain metastases followed by longitudinal MRI. J Vis Exp (2014) 0.76
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies. Oncotarget (2015) 0.76
Evaluating Changes to Blood-Brain Barrier Integrity in Brain Metastasis over Time and after Radiation Treatment. Transl Oncol (2016) 0.76
Safety and efficacy of the combination of T-DM1 with radiotherapy of the central nervous system in a patient with HER2-positive metastatic breast cancer: case study and review of the literature. Ecancermedicalscience (2015) 0.75
Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep (2017) 0.75
Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression. Breast Cancer Res (2013) 0.75
Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context. Int J Mol Sci (2017) 0.75
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature (2011) 5.49
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 4.14
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A (2008) 4.14
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol (2011) 4.12
CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol (2005) 4.11
Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity (2007) 4.07
PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell (2012) 3.83
The zinc finger protein cKrox directs CD4 lineage differentiation during intrathymic T cell positive selection. Nat Immunol (2005) 3.74
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (2012) 3.66
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Role of Nbs1 in the activation of the Atm kinase revealed in humanized mouse models. Nat Cell Biol (2005) 3.44
Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst (2002) 3.39
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res (2010) 3.35
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Breast cancer metastasis to the central nervous system. Am J Pathol (2005) 3.30
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res (2005) 3.07
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res (2004) 2.95
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol (2012) 2.87
'Coreceptor tuning': cytokine signals transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR. Nat Immunol (2007) 2.80
Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer (2003) 2.77
Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity (2011) 2.69
Deletion of CD4 and CD8 coreceptors permits generation of alphabetaT cells that recognize antigens independently of the MHC. Immunity (2007) 2.66
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res (2006) 2.61
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst (2005) 2.60
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol (2006) 2.53
Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer (2007) 2.52
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol (2008) 2.51
EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell (2009) 2.50
Cortical surface registration for image-guided neurosurgery using laser-range scanning. IEEE Trans Med Imaging (2003) 2.47
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 2.44
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin Cancer Res (2004) 2.41
Scientific collaboration results in higher citation rates of published articles. Pharmacotherapy (2006) 2.39
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation. Nat Cell Biol (2009) 2.38
Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res (2006) 2.36
Regulation of AID expression in the immune response. J Exp Med (2007) 2.35
Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest (2004) 2.31
Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med (2013) 2.31
Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci (2013) 2.30
Distinct functions for the transcription factors GATA-3 and ThPOK during intrathymic differentiation of CD4(+) T cells. Nat Immunol (2008) 2.29
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood (2002) 2.28
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood (2002) 2.28
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med (2007) 2.19
Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells. Nat Immunol (2010) 2.19
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res (2008) 2.15
NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity (2012) 2.14
Remission in dermatitis herpetiformis: a cohort study. Arch Dermatol (2010) 2.14
BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation. J Biol Chem (2008) 2.12
Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis (2008) 2.11
AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J Exp Med (2008) 2.10
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood (2010) 2.09
Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res (2005) 2.06
Global regulation of promoter melting in naive lymphocytes. Cell (2013) 2.05
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol (2014) 2.04